

New claim 85 is directed to the method of claim 84 in which the antigen-presenting cell is an activated B lymphocyte. Support for this claim can be found at page 10, lines 28-31 and Example 1 at page 14.

New claim 86 is directed to the method of claim 85 in which the antigen-presenting cell is a splenic activated B lymphocyte. Support for this claim can be found in Example 1 at page 14.

New claim 87 is directed to the method of claim 82 in which the antigen-presenting cell is a lymphoid cell. Support for this claim can be found at page 10, lines 8-9.

New claims 88 and 89 are directed to the method of claim 82 in which the antigen-presenting cell is a peripheral blood lymphocyte or a bone marrow cell, respectively. Support for these claims can be found at page 10, lines 35-38.

New claim 92 is directed to the method of claim 82 in which the anti-gp39 antibody is an anti-human gp39 antibody. Support for this claim can be found at page 27, in Example 6, Experiment 1.

New claims 93 and 94 are directed to the method of claim 82 in which the anti-gp39 antibody is a humanized anti-human gp39 antibody or a chimeric anti-human gp39 antibody, respectively. Support for these claims can be found at page 8, lines 16-26.

No new matter has been added by way of this amendment.

CONCLUSION

In view of the foregoing amendment and remarks, all claims in this application are believed to be in condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue. If any issue remains in connection herewith, the Examiner is respectfully invited to call the undersigned to discuss same.

Dated: September 23, 2005

Respectfully submitted,

By: Lynn Russo

Lynn M. Russo, Ph.D.
Reg. No. 54, 071
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant